Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Craniocerebral Trauma

ClinicalTrials.gov lists 3,504 trials for Craniocerebral Trauma or a narrower condition beneath it. VA Office of Research and Development has the most among industry and government lead sponsors, with 85.

MeSH D006259 Nervous System Diseases C10 C26
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 139 Phase 1/2 Phase 1/2 49 Phase 2 Phase 2 197 Phase 2/3 Phase 2/3 42 Phase 3 Phase 3 121 Phase 4 Phase 4 108 Not applicable Not applicable 1,759 Observational Observational 1,087 Phase 1 Phase 1 139 Phase 1/2 Phase 1/2 49 Phase 2 Phase 2 197 Phase 2/3 Phase 2/3 42 Phase 3 Phase 3 121 Phase 4 Phase 4 108 Not applicable Not applicable 1,759 Observational Observational 1,087

Trials per phase (log scale)

1 more section with rows

231 of the 3,504 trials are tagged with Craniocerebral Trauma itself; the rest are tagged with a narrower condition beneath it.

Get the Craniocerebral Trauma report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Craniocerebral Trauma trials start? (34)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 17 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access)

Top of scale: 277

1991: 1 trials (Phase 3 1) 1992: 1 trials (Observational 1) 1993: 1 trials (Phase 3 1) 1996: 2 trials (Not applicable 1, Phase 2 1) 1997: 2 trials (Observational 1, Phase 2 1) 1998: 4 trials (Observational 3, Phase 3 1) 1999: 1 trials (Not applicable 1) 2000: 3 trials (Observational 2, Not applicable 1) 2001: 4 trials (Observational 2, Phase 3 1, Phase 1 1) 2002: 21 trials (Observational 2, Not applicable 4, Phase 4 6, Phase 3 3, Phase 2 1, Phase 1/2 1, Phase 1 4) 2003: 30 trials (Observational 8, Not applicable 8, Phase 4 4, Phase 3 3, Phase 2/3 3, Phase 2 4) 2004: 27 trials (Observational 8, Not applicable 10, Phase 4 2, Phase 3 1, Phase 2/3 1, Phase 2 3, Phase 1 2) 2005: 35 trials (Observational 10, Not applicable 10, Phase 4 3, Phase 3 3, Phase 2 5, Phase 1/2 2, Phase 1 2) 2006: 32 trials (Observational 8, Not applicable 8, Phase 4 3, Phase 3 3, Phase 2/3 3, Phase 2 3, Phase 1 4) 2007: 55 trials (Observational 27, Not applicable 11, Phase 4 6, Phase 3 4, Phase 2/3 1, Phase 2 2, Phase 1 4) 2008: 67 trials (Other 1, Observational 22, Not applicable 24, Phase 4 3, Phase 3 3, Phase 2/3 2, Phase 2 5, Phase 1/2 4, Phase 1 3) 2009: 63 trials (Observational 18, Not applicable 22, Phase 4 2, Phase 3 3, Phase 2/3 1, Phase 2 10, Phase 1/2 3, Phase 1 4) 2010: 80 trials (Observational 29, Not applicable 21, Phase 4 4, Phase 3 8, Phase 2/3 1, Phase 2 11, Phase 1/2 2, Phase 1 4) 2011: 109 trials (Observational 43, Not applicable 31, Phase 4 5, Phase 3 7, Phase 2/3 2, Phase 2 10, Phase 1/2 5, Phase 1 6) 2012: 100 trials (Observational 38, Not applicable 38, Phase 4 6, Phase 3 3, Phase 2 5, Phase 1/2 4, Phase 1 6) 2013: 130 trials (Observational 35, Not applicable 64, Phase 4 7, Phase 3 2, Phase 2/3 2, Phase 2 13, Phase 1/2 1, Phase 1 6) 2014: 155 trials (Observational 37, Not applicable 81, Phase 4 5, Phase 3 6, Phase 2/3 2, Phase 2 18, Phase 1/2 2, Phase 1 4) 2015: 160 trials (Observational 55, Not applicable 84, Phase 4 3, Phase 3 3, Phase 2/3 2, Phase 2 6, Phase 1/2 1, Phase 1 6) 2016: 191 trials (Observational 55, Not applicable 103, Phase 4 4, Phase 3 7, Phase 2/3 3, Phase 2 9, Phase 1/2 4, Phase 1 6) 2017: 179 trials (Observational 52, Not applicable 101, Phase 4 4, Phase 3 3, Phase 2/3 1, Phase 2 9, Phase 1/2 3, Phase 1 6) 2018: 202 trials (Observational 64, Not applicable 112, Phase 4 2, Phase 3 9, Phase 2 6, Phase 1/2 2, Phase 1 7) 2019: 218 trials (Observational 64, Not applicable 128, Phase 4 2, Phase 3 5, Phase 2/3 2, Phase 2 12, Phase 1/2 2, Phase 1 3) 2020: 195 trials (Observational 60, Not applicable 104, Phase 4 7, Phase 3 6, Phase 2/3 1, Phase 2 7, Phase 1/2 1, Phase 1 9) 2021: 277 trials (Observational 91, Not applicable 157, Phase 4 5, Phase 3 5, Phase 2/3 2, Phase 2 5, Phase 1/2 4, Phase 1 8) 2022: 191 trials (Observational 64, Not applicable 107, Phase 3 5, Phase 2/3 2, Phase 2 5, Phase 1/2 3, Phase 1 5) 2023: 218 trials (Observational 71, Not applicable 122, Phase 4 5, Phase 3 5, Phase 2 8, Phase 1 7) 2024: 265 trials (Observational 84, Not applicable 141, Phase 4 5, Phase 3 8, Phase 2/3 2, Phase 2 12, Phase 1/2 2, Phase 1 11) 2025: 237 trials (Observational 66, Not applicable 134, Phase 4 6, Phase 3 7, Phase 2/3 4, Phase 2 11, Phase 1/2 1, Phase 1 8)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 220
2025 237
2024 265
2023 218
2022 191
2021 277
2020 195
2019 218
2018 202
2017 179

Forecast of the full-year count, planned starts included, not rows of this table: about 240 trials starting in 2026 and about 240 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 350 trials still running at the 2026-10-09 snapshot; registered median of 26 months across 1,944 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Craniocerebral Trauma trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 139
Phase 1/2 49
Phase 2 197
Phase 2/3 42
Phase 3 121
Phase 4 108
Not applicable 1,759
Observational 1,087
Expanded access 2

How many Craniocerebral Trauma trials are recruiting? (11)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 210
Recruiting 464
Enrolling by invitation 55
Active, not recruiting 93
Available 1

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Craniocerebral Trauma trials? (1)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
VA Office of Research and Development 85

Which drugs are being tested for Craniocerebral Trauma? (1)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
DEXMEDETOMIDINE 13

Interventions as named in the registry (14)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Hyperbaric Oxygen 22
Aerobic exercise 16
acid tranexamic 16
Treatment As Usual 13
somatropin AQ 12

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Craniocerebral Trauma trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 459 21
Increased intracranial hemorrhage on serial head CT 239 1
CNS 125 1
Shock 121 3
Acute Kidney Injury 118 1

Which publications cover Craniocerebral Trauma? (343)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Sub-conditions in MeSH (9)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages